Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Joon Ho Moon  (Moon JH) 7 Articles
Diabetes, obesity and metabolism
Metabolic Phenotypes of Women with Gestational Diabetes Mellitus Affect the Risk of Adverse Pregnancy Outcomes
Joon Ho Moon, Sookyung Won, Hojeong Won, Heejun Son, Tae Jung Oh, Soo Heon Kwak, Sung Hee Choi, Hak Chul Jang
Endocrinol Metab. 2025;40(2):247-257.   Published online November 28, 2024
DOI: https://doi.org/10.3803/EnM.2024.2089
  • 1,321 View
  • 64 Download
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Gestational diabetes mellitus (GDM) affects women with diverse pathological phenotypes, but little is known about the effects of this variation on perinatal outcomes. We explored the metabolic phenotypes of GDM and their impact on adverse pregnancy outcomes.
Methods
Women diagnosed with gestational glucose intolerance or GDM were categorized into subgroups according to their prepregnancy body mass index (BMI) and the median values of the gestational Matsuda and Stumvoll indices. Logistic regression analysis was employed to assess the odds of adverse pregnancy outcomes, such as large-for-gestational age (LGA), small-for-gestational age, preterm birth, low Apgar score, and cesarean section.
Results
A total of 309 women were included, with a median age of 31 years and a median BMI of 22.3 kg/m2. Women with a higher pre-pregnancy BMI had a higher risk of LGA newborns (adjusted odds ratio [aOR] for pre-pregnancy BMI ≥25 kg/m2 compared to 20–23 kg/m2, 4.26; 95% confidence interval [CI], 1.99 to 9.12; P<0.001; P for trend=0.001), but the risk of other adverse pregnancy outcomes did not differ according to pre-pregnancy BMI. Women with insulin resistance had a higher risk of LGA (aOR, 1.88; 95% CI, 1.02 to 3.47; P=0.043) and cesarean section (aOR, 2.12; 95% CI, 1.29 to 3.50; P=0.003) than women in the insulin-sensitive group. In contrast, defective β-cell function did not affect adverse pregnancy outcomes.
Conclusion
Different metabolic phenotypes of GDM were associated with heterogeneous pregnancy outcomes. Women with obesity and those with insulin resistance are at greater risk of adverse outcomes and might need strict glycemic management during pregnancy.

Citations

Citations to this article as recorded by  
  • Gestational Diabetes Mellitus: Mechanisms Underlying Maternal and Fetal Complications
    Jooyeop Lee, Na Keum Lee, Joon Ho Moon
    Endocrinology and Metabolism.2025; 40(1): 10.     CrossRef
Close layer
Diabetes, obesity and metabolism
Metabolic Consequences of Glucagon-Like Peptide-1 Receptor Agonist Shortage: Deterioration of Glycemic Control in Type 2 Diabetes
Hun Jee Choe, Michael A. Nauck, Joon Ho Moon
Endocrinol Metab. 2025;40(1):156-160.   Published online November 25, 2024
DOI: https://doi.org/10.3803/EnM.2024.2150
  • 955 View
  • 58 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
In the context of a global shortage of glucagon-like peptide-1 (GLP-1) receptor agonists, we assessed the impact of discontinuing dulaglutide on metabolic control in individuals with type 2 diabetes. Our analysis included data from 69 individuals and revealed a significant deterioration in glycemic control following the discontinuation. Specifically, the average hemoglobin A1c level increased from 7.0%±0.9% to 8.1%±1.4% (P<0.001), and fasting glucose levels rose from 129±31 to 156±50 mg/dL (P<0.001) within 3 months after stopping the medication. Alternative treatments such as dipeptidyl peptidase-4 inhibitors and sodium glucose cotransporter- 2 inhibitors were insufficient substitutes, highlighting the essential role of continuous GLP-1 receptor agonist therapy in maintaining metabolic health.
Close layer
Diabetes, obesity and metabolism
Gestational Diabetes Mellitus: Mechanisms Underlying Maternal and Fetal Complications
Jooyeop Lee, Na Keum Lee, Joon Ho Moon
Endocrinol Metab. 2025;40(1):10-25.   Published online January 23, 2025
DOI: https://doi.org/10.3803/EnM.2024.2264
  • 4,081 View
  • 213 Download
  • 2 Crossref
AbstractAbstract PDFPubReader   ePub   
Gestational diabetes mellitus (GDM) affects over 10% of all pregnancies, both in Korea and worldwide. GDM not only increases the risk of adverse pregnancy outcomes such as preeclampsia, preterm birth, macrosomia, neonatal hypoglycemia, and shoulder dystocia, but it also significantly increases the risk of developing postpartum type 2 diabetes mellitus and cardiovascular disease in the mother. Additionally, GDM is linked to a higher risk of childhood obesity and diabetes in offspring, as well as neurodevelopmental disorders, including autistic spectrum disorder. This review offers a comprehensive summary of clinical epidemiological studies concerning maternal and fetal complications and explores mechanistic investigations that reveal the underlying pathophysiology.

Citations

Citations to this article as recorded by  
  • Unveiling Gestational Diabetes: An Overview of Pathophysiology and Management
    Rahul Mittal, Karan Prasad, Joana R. N. Lemos, Giuliana Arevalo, Khemraj Hirani
    International Journal of Molecular Sciences.2025; 26(5): 2320.     CrossRef
  • Advancing Early Prediction of Gestational Diabetes Mellitus with Circular RNA Biomarkers
    Joon Ho Moon, Sung Hee Choi
    Diabetes & Metabolism Journal.2025; 49(3): 403.     CrossRef
Close layer
Diabetes, obesity and metabolism
Amelioration of Insulin Resistance after Delivery Is Associated with Reduced Risk of Postpartum Diabetes in Women with Gestational Diabetes Mellitus
Heejun Son, Joon Ho Moon, Sung Hee Choi, Nam H. Cho, Soo Heon Kwak, Hak Chul Jang
Endocrinol Metab. 2024;39(5):701-710.   Published online August 21, 2024
DOI: https://doi.org/10.3803/EnM.2024.1974
  • 2,218 View
  • 66 Download
  • 1 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Identifying risk factors for postpartum type 2 diabetes in women with gestational diabetes mellitus (GDM) is crucial for effective interventions. We examined whether changes in insulin sensitivity after delivery affects the risk of type 2 diabetes in women with GDM.
Methods
This prospective cohort study included 347 women with GDM or gestational impaired glucose tolerance, who attended the follow-up visits at 2 months postpartum and annually thereafter. Changes in insulin sensitivity were calculated using the Matsuda index at GDM diagnosis and at 2 months postpartum (ΔMatsuda index). After excluding women with pregestational diabetes or those followed up only once, we analyzed the risk of postpartum type 2 diabetes based on the ΔMatsuda index tertiles.
Results
The incidence of type 2 diabetes at the two-month postpartum visit decreased with increasing ΔMatsuda index tertiles (16.4%, 9.5%, and 1.8%, P=0.001). During a 4.1-year follow-up, 26 out of 230 women who attended more than two follow-up visits (11.3%) developed type 2 diabetes. Compared to the lowest tertile, subjects in the highest ΔMatsuda index tertile showed a significantly reduced risk of type 2 diabetes (hazard ratio, 0.33; 95% confidence interval, 0.12 to 0.93; P=0.036) after adjusting for confounders.
Conclusion
Improvement in insulin sensitivity after delivery is associated with a reduced risk of postpartum type 2 diabetes in women with GDM. Postpartum changes in insulin sensitivity could be a useful prediction for future type 2 diabetes development in women with GDM.

Citations

Citations to this article as recorded by  
  • Gestational Diabetes Mellitus: Mechanisms Underlying Maternal and Fetal Complications
    Jooyeop Lee, Na Keum Lee, Joon Ho Moon
    Endocrinology and Metabolism.2025; 40(1): 10.     CrossRef
  • Evaluation of Maternal Factors Affecting Postpartum Insulin Resistance Markers in Mothers with Gestational Diabetes—A Case–Control Study
    Karolina Karcz, Paulina Gaweł, Barbara Królak-Olejnik
    Nutrients.2024; 16(22): 3871.     CrossRef
Close layer
Diabetes, obesity and metabolism
Triglyceride-Glucose Index Predicts Future Atherosclerotic Cardiovascular Diseases: A 16-Year Follow-up in a Prospective, Community-Dwelling Cohort Study
Joon Ho Moon, Yongkang Kim, Tae Jung Oh, Jae Hoon Moon, Soo Heon Kwak, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi, Nam H. Cho
Endocrinol Metab. 2023;38(4):406-417.   Published online August 3, 2023
DOI: https://doi.org/10.3803/EnM.2023.1703
  • 10,801 View
  • 298 Download
  • 18 Web of Science
  • 18 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
While the triglyceride-glucose (TyG) index is a measure of insulin resistance, its association with cardiovascular disease (CVD) has not been well elucidated. We evaluated the TyG index for prediction of CVDs in a prospective large communitybased cohort.
Methods
Individuals 40 to 70 years old were prospectively followed for a median 15.6 years. The TyG index was calculated as the Ln [fasting triglycerides (mg/dL)×fasting glucose (mg/dL)/2]. CVDs included any acute myocardial infarction, coronary artery disease or cerebrovascular disease. We used a Cox proportional hazards model to estimate CVD risks according to quartiles of the TyG index and plotted the receiver operating characteristics curve for the incident CVD.
Results
Among 8,511 subjects (age 51.9±8.8 years; 47.5% males), 931 (10.9%) had incident CVDs during the follow-up. After adjustment for age, sex, body mass index, diabetes mellitus, hypertension, total cholesterol, smoking, alcohol, exercise, and C-reactive protein, subjects in the highest TyG quartile had 36% increased risk of incident CVD compared with the lowest TyG quartile (hazard ratio, 1.36; 95% confidence interval, 1.10 to 1.68). Carotid plaque, assessed by ultrasonography was more frequent in subjects in the higher quartile of TyG index (P for trend=0.049 in men and P for trend <0.001 in women). The TyG index had a higher predictive power for CVDs than the homeostasis model assessment of insulin resistance (HOMA-IR) (area under the curve, 0.578 for TyG and 0.543 for HOMA-IR). Adding TyG index on diabetes or hypertension alone gave sounder predictability for CVDs.
Conclusion
The TyG index is independently associated with future CVDs in 16 years of follow-up in large, prospective Korean cohort.

Citations

Citations to this article as recorded by  
  • Elevated triglyceride-glucose index as a predictor of carotid plaque incidence: Insights from a comprehensive meta-analysis
    Arankesh Mahadevan, Bhavin A. Patel, Sashwath Srikanth, Raja Godasi, Rupak Desai
    The American Journal of the Medical Sciences.2025; 369(2): 197.     CrossRef
  • Analysis of the correlation between the serum triglyceride glucose index and the risk of death in patients on maintenance hemodialysis: a retrospective cohort study
    Xiaokeng Chi, Shuxin Chen, Zhe Huang, Rong Zhou, Zhicheng Su, Qiujun Mai, Yilin Xu, Jianxin Wan
    PeerJ.2025; 13: e18781.     CrossRef
  • Assessing the predictive value of elevated triglycerides, triglyceride-glucose index (TyG), and TG/HDL ratios for cardiovascular disease and mortality during 20 years of follow-up: Tehran lipid and glucose study
    Shayesteh Khalili, Atieh Amouzegar, Seyed Sattar Dorost, Fereidoun Azizi, Aryan Salahi-Niri
    Clinical Biochemistry.2025; 136: 110891.     CrossRef
  • Association between triglyceride-glucose index and carotid atherosclerosis in Chinese steelworkers: a cross-sectional study
    Haoyue Cao, Qinglin Li, Juxiang Yuan
    Scientific Reports.2025;[Epub]     CrossRef
  • Association between the triglyceride-glucose index and silent myocardial infarction in the general population
    Min Dai, Dongze Li, Jing Yu, Yi Liu, Qin Zhang, Wei Zhang, Yan Zhong, Zhi Wan, Menglin Tang, Yongli Gao, Li Rao
    Scientific Reports.2025;[Epub]     CrossRef
  • Integrative Multi‐Omics and Routine Blood Analysis Using Deep Learning: Cost‐Effective Early Prediction of Chronic Disease Risks
    Zhibin Dong, Pei Li, Yi Jiang, Zhihan Wang, Shihui Fu, Hebin Che, Meng Liu, Xiaojing Zhao, Chunlei Liu, Chenghui Zhao, Qin Zhong, Chongyou Rao, Siwei Wang, Suyuan Liu, Dayu Hu, Dongjin Wang, Juntao Gao, Kai Guo, Xinwang Liu, En Zhu, Kunlun He
    Advanced Science.2025;[Epub]     CrossRef
  • Impact of steatotic liver disease categories on atrial fibrillation in type 2 diabetes: a nationwide study
    So Hyun Cho, Gyuri Kim, Kyu-na Lee, Rosa Oh, Ji Yoon Kim, Myunghwa Jang, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Kyungdo Han, Jae Hyeon Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Construction and validation of a nomogram for predicting diabetes remission at 3 months after bariatric surgery in patients with obesity combined with type 2 diabetes mellitus
    Kaisheng Yuan, Bing Wu, Ruiqi Zeng, Fuqing Zhou, Ruixiang Hu, Cunchuan Wang
    Diabetes, Obesity and Metabolism.2024; 26(1): 169.     CrossRef
  • Association between the triglyceride glucose index and chronic total coronary occlusion: A cross-sectional study from southwest China
    Kaiyong Xiao, Huili Cao, Bin Yang, Zhe Xv, Lian Xiao, Jianping Wang, Shuiqing Ni, Hui Feng, Zhongwei He, Lei Xv, Juan Li, Dongmei Xv
    Nutrition, Metabolism and Cardiovascular Diseases.2024; 34(4): 850.     CrossRef
  • The association between TyG and all-cause/non-cardiovascular mortality in general patients with type 2 diabetes mellitus is modified by age: results from the cohort study of NHANES 1999–2018
    Younan Yao, Bo Wang, Tian Geng, Jiyan Chen, Wan Chen, Liwen Li
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Comparison of triglyceride glucose index and modified triglyceride glucose indices in prediction of cardiovascular diseases in middle aged and older Chinese adults
    Cancan Cui, Yitian Qi, Jiayin Song, Xinyun Shang, Tianjiao Han, Ning Han, Siqi Yue, Yining Zha, Zhonghang Xu, Jiannan Li, Lin Liu
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Triglyceride-glucose index predicts type 2 diabetes mellitus more effectively than oral glucose tolerance test-derived insulin sensitivity and secretion markers
    Min Jin Lee, Ji Hyun Bae, Ah Reum Khang, Dongwon Yi, Mi Sook Yun, Yang Ho Kang
    Diabetes Research and Clinical Practice.2024; 210: 111640.     CrossRef
  • Prognostic value of triglyceride-glucose index for left ventricular remodeling in nondiabetic ST-elevation myocardial infarction patients
    Tolga Han Efe, Engin Algül
    Biomarkers in Medicine.2024; 18(6): 243.     CrossRef
  • Triglyceride-Glucose Index as Predictor for Hypertension, CHD and STROKE Risk among Non-Diabetic Patients: A NHANES Cross-Sectional Study 2001–2020
    Bisher Sawaf, Sarya Swed, Hidar Alibrahim, Haidara Bohsas, Tirth Dave, Mohamad Nour Nasif, Wael Hafez, Fatema Ali Asgar Tashrifwala, Yazan Khair Eldien Jabban, Safwan Al-Rassas, Heba haj Saleh, Abdul Rehman Zia Zaidi, Baraa Alghalyini, Shaymaa Abdelmaboud
    Journal of Epidemiology and Global Health.2024; 14(3): 1152.     CrossRef
  • An Increasing Triglyceride–Glucose Index Is Associated with a Pro-Inflammatory and Pro-Oxidant Phenotype
    Beverley Adams-Huet, Ishwarlal Jialal
    Journal of Clinical Medicine.2024; 13(13): 3941.     CrossRef
  • Inflammatory and Metabolic Predictors of Mortality in Pulmonary Thromboembolism: A Focus on the Triglyceride–Glucose Index and Pan-Immune Inflammation Value
    Murat Bilgin, Emre Akkaya, Recep Dokuyucu
    Journal of Clinical Medicine.2024; 13(19): 6008.     CrossRef
  • The role of the triglyceride-glucose index as a biomarker of cardio-metabolic syndromes
    Verena Gounden, Sridevi Devaraj, Ishwarlal Jialal
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Evaluation of the novel three lipid indices for predicting five- and ten-year incidence of cardiovascular disease: findings from Kerman coronary artery disease risk factors study (KERCADRS)
    Alireza Jafari, Hamid Najafipour, Mitra Shadkam, Sina Aminizadeh
    Lipids in Health and Disease.2023;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Joon Ho Moon, Kyuho Kim, Sung Hee Choi
Endocrinol Metab. 2022;37(4):575-586.   Published online August 29, 2022
DOI: https://doi.org/10.3803/EnM.2022.402
  • 38,731 View
  • 729 Download
  • 28 Web of Science
  • 30 Crossref
AbstractAbstract PDFPubReader   ePub   
High levels of triglycerides (TG) and triglyceride-rich lipoproteins (TGRLs) confer a residual risk of cardiovascular disease after optimal low-density lipoprotein cholesterol (LDL-C)–lowering therapy. Consensus has been made that LDL-C is a non-arguable primary target for lipid lowering treatment, but the optimization of TGRL for reducing the remnant risk of cardiovascular diseases is urged. Omega-3 fatty acids and fibrates are used to reduce TG levels, but many patients still have high TG and TGRL levels combined with low high-density lipoprotein concentration that need to be ideally treated. Lipoprotein lipase (LPL) is a key regulator for TGs that hydrolyzes TGs to glycerol and free fatty acids in lipoprotein particles for lipid storage and consumption in peripheral organs. A deeper understanding of human genetics has enabled the identification of proteins regulating the LPL activity, which include the apolipoproteins and angiopoietin-like families. Novel therapeutic approach such as antisense oligonucleotides and monoclonal antibodies that regulate TGs have been developed in recent decades. In this article, we focus on the biology of LPL and its modulators and review recent clinical application, including genetic studies and clinical trials of novel therapeutics. Optimization of LPL activity to lower TG levels could eventually reduce incident atherosclerotic cardiovascular disease in conjunction with successful LDL-C reduction.

Citations

Citations to this article as recorded by  
  • The Relationship Between Remnant Cholesterol and Visceral Adipose Tissue: A National Cross-Sectional Study
    Zhaoxiang Wang, Shao Zhong, Menghuan Wu, Xuejing Shao, Tian Gu, Mengjiao Xu, Qichao Yang
    Hormone and Metabolic Research.2025; 57(01): 47.     CrossRef
  • Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
    Jakub Michal Zimodro, Manfredi Rizzo, Ioanna Gouni-Berthold
    Pharmaceuticals.2025; 18(2): 147.     CrossRef
  • Insights into Causal Associations of Lipid Traits and Lipid-modifying Drug Targets with Uric Acid and Risk of Gout
    Chenfeng Zou, Bei Yang, Jiaying Zhang, Yuying Zhang, Dewei Ye, Hanyu Zhu, Tao Bai, Guozhi Jiang
    Phenomics.2025;[Epub]     CrossRef
  • Associations of intra‐pancreatic fat deposition with triglyceride‐rich lipoproteins and lipoprotein lipase
    Yutong Liu, Loren Skudder‐Hill, Wandia Kimita, Xiatiguli Shamaitijiang, Ivana R. Sequeira‐Bisson, Maxim S. Petrov
    Diabetes, Obesity and Metabolism.2025; 27(6): 3233.     CrossRef
  • Association between atherogenic index of plasma level and cardiovascular events in patients with obstructive sleep apnea: The sleep heart health study
    Lixia Wang, Xinjie Hui, Rong Huang, Yi Xiao
    Sleep Medicine.2025; 129: 375.     CrossRef
  • HDL-Cholesterol and Triglycerides Dynamics: Essential Players in Metabolic Syndrome
    Sebastià Alcover, Lisaidy Ramos-Regalado, Gabriela Girón, Natàlia Muñoz-García, Gemma Vilahur
    Antioxidants.2025; 14(4): 434.     CrossRef
  • The Role of Calcium Ions in Restoring Lipase Activity of Recombinant Human Lipoprotein Lipase Expressed in Bacteria
    Chong Lee Ng, Theam Soon Lim, Yee Siew Choong
    Molecular Biotechnology.2025;[Epub]     CrossRef
  • Three-Dimensional Hydrogel Culture Reveals Novel Differentiation Potential of Human Bone Marrow-Derived Stem Cells
    Hye Jeong Lee, Le Na Lau, Sharanbir K. Sidhu, Joo-Young Park, In-Sung Luke Yeo
    Prosthesis.2025; 7(3): 52.     CrossRef
  • The chylomicron saga: time to focus on postprandial metabolism
    Alejandro Gugliucci
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Sanghuangporus vaninii extract ameliorates hyperlipidemia in rats by mechanisms identified with transcriptome analysis
    Ning Gao, Yuanzhen Liu, Guangjie Liu, Bo Liu, Yupeng Cheng
    Food Science & Nutrition.2024; 12(5): 3360.     CrossRef
  • Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
    Monika I. Konaklieva, Balbina J. Plotkin
    Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
  • Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024
    Harold Edward Bays, Carol Kirkpatrick, Kevin C. Maki, Peter P. Toth, Ryan T. Morgan, Justin Tondt, Sandra Michelle Christensen, Dave Dixon, Terry A. Jacobson
    Obesity Pillars.2024; 10: 100108.     CrossRef
  • Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
    Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang
    Diabetes & Metabolism Journal.2024; 48(2): 184.     CrossRef
  • Xanthohumol, a prenylated chalcone, regulates lipid metabolism by modulating the LXRα/RXR-ANGPTL3-LPL axis in hepatic cell lines and high-fat diet-fed zebrafish models
    Wan-Yun Gao, Pei-Yi Chen, Hao-Jen Hsu, Je-Wen Liou, Chia-Ling Wu, Ming-Jiuan Wu, Jui-Hung Yen
    Biomedicine & Pharmacotherapy.2024; 174: 116598.     CrossRef
  • Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024
    Harold Edward Bays, Carol F. Kirkpatrick, Kevin C. Maki, Peter P. Toth, Ryan T. Morgan, Justin Tondt, Sandra Michelle Christensen, Dave L. Dixon, Terry A. Jacobson
    Journal of Clinical Lipidology.2024; 18(3): e320.     CrossRef
  • Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3‐year prospective cohort study
    Ming‐Ling Chang, Jennifer Tai, Jur‐Shan Cheng, Wei‐Ting Chen, Sien‐Sing Yang, Cheng‐Hsun Chiu, Rong‐Nan Chien
    Diabetes, Obesity and Metabolism.2024; 26(7): 2969.     CrossRef
  • Efficacy and safety of omega‐3‐acid ethyl acetate 90 capsules in severe hypertriglyceridemia: A randomized, controlled, multicenter study
    Wang Zhao, Yangang Wang, Jin Li, Tao Chen, Delu Yin, Hailong Dai, Zhuhua Yao, Shuiping Zhao
    Lipids.2024; 59(5): 145.     CrossRef
  • Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease
    Rui Shang, Brian Rodrigues
    Journal of Pharmacy & Pharmaceutical Sciences.2024;[Epub]     CrossRef
  • Targeting Apolipoprotein C-III for the Management of Severe Hypertriglyceridemia: Current Research and Future Directions
    Mili Shah, Abisheikh Sharma, Mohammed Ayyad, Ethan Swartz, Danyaal Jafrani, Dhir Gala
    Cureus.2024;[Epub]     CrossRef
  • Angiopoietin-like Proteins and Lipoprotein Lipase: The Waltz Partners That Govern Triglyceride-Rich Lipoprotein Metabolism? Impact on Atherogenesis, Dietary Interventions, and Emerging Therapies
    Alejandro Gugliucci
    Journal of Clinical Medicine.2024; 13(17): 5229.     CrossRef
  • Proteo-genomic analyses in relatively lean Chinese adults identify proteins and pathways that affect general and central adiposity levels
    Andri Iona, Pang Yao, Alfred Pozarickij, Christiana Kartsonaki, Saredo Said, Neil Wright, Kuang Lin, Iona Millwood, Hannah Fry, Mohsen Mazidi, Baihan Wang, Yiping Chen, Huaidong Du, Ling Yang, Daniel Avery, Dan Schmidt, Dianjianyi Sun, Pei Pei, Jun Lv, Ca
    Communications Biology.2024;[Epub]     CrossRef
  • Molecular Pathways Linking High-Fat Diet and PM2.5 Exposure to Metabolically Abnormal Obesity: A Systematic Review and Meta-Analysis
    Sagrario Lobato, Víctor Manuel Salomón-Soto, Claudia Magaly Espinosa-Méndez, María Nancy Herrera-Moreno, Beatriz García-Solano, Ernestina Pérez-González, Facundo Comba-Marcó-del-Pont, Mireya Montesano-Villamil, Marco Antonio Mora-Ramírez, Claudia Mancilla
    Biomolecules.2024; 14(12): 1607.     CrossRef
  • High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis
    Franziska Schmalz, Janett Fischer, Hamish Innes, Stephan Buch, Christine Möller, Madlen Matz-Soja, Witigo von Schönfels, Benjamin Krämer, Bettina Langhans, Alexandra Klüners, Michael Soyka, Felix Stickel, Jacob Nattermann, Christian P. Strassburg, Thomas
    JHEP Reports.2023; 5(4): 100684.     CrossRef
  • Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations
    Dieter Lütjohann, Hans-Ulrich Klör, Frans Stellaard
    Nutrients.2023; 15(9): 2202.     CrossRef
  • Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study and in vitro hepatic lipid homeostasis gene expression
    Tien-Yuan Wu, Ni Tien, Cheng-Li Lin, Yu-Cun Cheah, Chung Y. Hsu, Fuu-Jen Tsai, Yi-Jen Fang, Yun-Ping Lim
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
    Alejandro Gugliucci
    Journal of Clinical Medicine.2023; 12(13): 4399.     CrossRef
  • Sugar and Dyslipidemia: A Double-Hit, Perfect Storm
    Alejandro Gugliucci
    Journal of Clinical Medicine.2023; 12(17): 5660.     CrossRef
  • Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
    Sang Heon Suh, Soo Wan Kim
    Diabetes & Metabolism Journal.2023; 47(5): 612.     CrossRef
  • Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
    Elena Valeria Fuior, Evangelia Zvintzou, Theodosios Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E. Kypreos
    Biomedicines.2023; 11(10): 2696.     CrossRef
  • Developing a model to predict the early risk of hypertriglyceridemia based on inhibiting lipoprotein lipase (LPL): a translational study
    Julia Hernandez-Baixauli, Gertruda Chomiciute, Juan María Alcaide-Hidalgo, Anna Crescenti, Laura Baselga-Escudero, Hector Palacios-Jordan, Elisabet Foguet-Romero, Anna Pedret, Rosa M. Valls, Rosa Solà, Miquel Mulero, Josep M. Del Bas
    Scientific Reports.2023;[Epub]     CrossRef
Close layer
A Case of Apical Hypertrohic Cardiomyopathy Associated with Pheochromocytoma.
Joon Ho Moon, Sung Woo Park, Sung Hee Ihm, Cheol Young Park, Ki Won Oh, Cheol Soo Choi, Seong Jin Lee, In Kyung Jung, Eun Gyung Hong, Hyeon Kyu Kim, Doo Man Kim, Jae Myung Yoo, Moon Gi Choi, Hyung Joon Yoo, So Young Ku, Soo Kee Min
J Korean Endocr Soc. 2004;19(5):522-527.   Published online October 1, 2004
  • 1,353 View
  • 18 Download
AbstractAbstract PDF
Pheochromocytomas often present with cardiovascular manifestations, such as arrhythmia, angina pectoris and acute myocardial infarction and so on. Both dilated and nonobstructive hypertrophic cardiomyopathies are also rare complications of pheochromocytomas. In hypertrophic cardiomyopathy, an apical variant form constitutes about 25% of cases in Japan, but only 1 to 2% of those in non-Japanese populations, including Korea. The cause of apical hypertrophic cardiomyopathy (AHC) remains unknown. Recently, some cases of AHC associated with pheochromocytomas have been reported, with catecholamine thought to be an important cause. AHC associated with a pheochromocytoma has never been previously reported in Korea. Herein is reported our experience of a case of apical hypertrophic cardiomyopathy associated a pheochromocytoma with a review of the literature
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP